Within adverse-risk AML, the impact of additional molecular abnormalities was further evaluated. Multivariable analysis was performed on a training set (n = 316) and identified IDH2 mutation as an independent favorable prognostic factor, and KRAS, MLL2, and TP53 mutations as unfavorable (P < ....
这使得我们能够有意义地、精确地合并成人AML的细胞遗传学和基因组学数据,并简化了医师进行风险分层的过程。 知识链接 参考文献: [1]Seema Biswas, Aarti Ramesh Achrekar, Priyanka Rajesh Ugale, et al.Validation of the 2022 European ...
该研究表明,对于FLT3-ITD突变但未接受FLT3抑制剂的AML患者,其风险分类应被视为高危组,治疗应依据高危组治疗方案。此外,在ECOG体能状态评分2-4的患者中,ELN-2022风险体系不能很好地预测远期生存。 参考文献:Chen E, Jiao C, Yu J, e...
这使得我们能够有意义地、精确地合并成人AML的细胞遗传学和基因组学数据,并简化了医师进行风险分层的过程。 知识链接 参考文献: [1]Seema Biswas, Aarti Ramesh Achrekar, Priyanka Rajesh Ugale, et al.Validation of the 2022 European Leukemianet Risk Stratification of Acute Myeloid Leukemia (AML).ASH 2024:...
在本次大会上,一项题为“Validation of the 2022 European Leukemianet Risk Stratification of Acute Myeloid Leukemia(2022年欧洲白血病网(ELN)急性髓系白血病(AML)风险分层的验证)”的研究入选壁报展示(P4310),为AML风险分层带来重要启示。本期特整理如下,供大家提前阅览。
KJArcher_hdcuremodels_06-13-2024.pdf README.md hdcuremodels_0.0.1.tar.gz 2022_ELN_Favorable_Code.Rmd R code for replicating results in Archer et al., "Improving risk stratification for 2022 European LeukemiaNet favorable-risk patients with acute myeloid leukemia" ...
et al. Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study. Leukemia 35, 1291–1300 (2021). https://doi.org/10.1038/s41375-020-01031-1 Download citation Received27 April 2020 Revised23 July 2020 Accepted14 August 2020 Published18 ...
2024, Cytometry Part B - Clinical Cytometry A Focus on Intermediate-Risk Acute Myeloid Leukemia: Sub-Classification Updates and Therapeutic Challenges 2022, Cancers Issue Highlights—July 2022 2022, Cytometry Part B - Clinical CytometryDetails regarding the original AML1310 trial collection data methods ...
In summary, ASXL1 mutations were associated with lower CR rate and shorter survival, particularly within the ELN Favorable genetic category and thus identify a previously unrecognized high-risk subgroup among older primary CN-AML patients. Exploratory analyses of ASXL1 mutations in the context of othe...
Due to the small number of prospective Minimal Residual Disease (MRD) driven studies, the MRD role in AML risk stratification is not clearly defined.The aim of this study was to evaluate the effect of MRD in a real-life setting. We retrospectively analyzed 124 patients with Favorable (FAV) ...